NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
27/01/2026
Voltar para busca
Dado oficial do USPTO
A2 BIO
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
46
Atualização mais recente
28/01/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 40, 42
Data de depósito
14/10/2021
Data de registro
27/01/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/01/2026
Última transação
28/01/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
01/05/2023
Primeiro uso no comércio
01/05/2023
Código do desenho
3
Tipo de titular
03
Localização do titular
Agoura Hills, CA
Examinador
WOO, SAMUEL M
Unidade examinadora
O70
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a black square with white frame and black border containing "A2" in white text in the lower right quadrant, with the word BIO in black text appearing under the number 2 and breaking the black and white border.
Titulares e representantes
Titulares
A2 Biotherapeutics, Inc.
Representantes
Joi A. White CARR & FERRELL LLP
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Therapeutics in the nature of cellsproteins and protein complexes for the treatment and prevention of cancer; biotherapeutics for the treatment and prevention of cancer; medicines for the treatment and prevention of cancer; pharmaceutical products for the treatment and prevention of cancer; therapeutic targetsproteins or protein complexesfor the treatment and prevention of cancer; therapeutic cellstherapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer; therapeutics and cell therapies in the nature of cellsproteins and protein complexes for the treatment of cancer; engineered cell therapies in the nature of cellsproteins and protein complexes for medical purposesthe treatment and prevention of cancer; engineered cell therapy platforms consisting of modified cellscell receptorsproteins and protein complexes; cell platforms consisting of modified cellscell receptorsproteins and protein complexes for the treatment and prevention of cancer; technology platforms for developing and engineering therapeutic cellstherapeutic proteinstherapeutic antibodiestherapeutics and cellular therapies for the treatment and prevention of cancer; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer; gene therapy productsgenetically engineered tissues for transplant purposes;
Classe 40
Custom manufacturing of therapeuticsbiotherapeuticsmedicinespharmaceuticals; manufacturing of cellstherapeutics and cell therapies for the treatment and prevention of cancer; biomanufacturing for othersmanufacturing of cellstherapeutics and cell therapies for the treatment and prevention of cancer using biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeuticscell therapiesbiologicsmedicinepharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing and engineering of biological cellscellular targetsproteinsantibodies for others for treatment and prevention of cancer;
Classe 42
Medical research services; pharmaceutical and biopharmaceutical research and development services; provision of medical and scientific research information in the fields of therapeuticsbiotherapeuticsmedicinespharmaceuticals; identification and development of therapeutic targets for others for the treatment and prevention of cancer; development of therapeutics and cell therapies for treatment and prevention of cancer; research and development of therapeutics and cell therapies targeting targets lost for the treatment and prevention of cancer; biotechnology researchdevelopmenttesting and analysis for the treatment of cancer; scientific research and development services; providing scientific information relating to treatment and prevention of cancer; researchdevelopmentengineering and testing services in the fields of therapeuticscell therapiesbiologicsmedicinepharmaceuticals; medical laboratory servicestissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services;
Publicações
Histórico de despachos e eventos da marca no USPTO.
46 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
27/01/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
02/01/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
02/01/2026
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/11/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/11/2025
DPCC
DIVISIONAL PROCESSING COMPLETE
10/11/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/11/2025
IUAF
USE AMENDMENT FILED
30/05/2025
DRRR
DIVISIONAL REQUEST RECEIVED
30/05/2025
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
30/05/2025
EISU
TEAS STATEMENT OF USE RECEIVED
30/05/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
20/05/2025
EX4G
SOU EXTENSION 4 GRANTED
20/05/2025
EXT4
SOU EXTENSION 4 FILED
19/05/2025
EEXT
SOU TEAS EXTENSION RECEIVED
19/05/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/11/2024
EX3G
SOU EXTENSION 3 GRANTED
07/11/2024
EXT3
SOU EXTENSION 3 FILED
07/11/2024
EEXT
SOU TEAS EXTENSION RECEIVED
07/11/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
15/05/2024
EX2G
SOU EXTENSION 2 GRANTED
14/05/2024
EXT2
SOU EXTENSION 2 FILED
14/05/2024
EEXT
SOU TEAS EXTENSION RECEIVED
14/05/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
21/11/2023
EX1G
SOU EXTENSION 1 GRANTED
17/11/2023
EXT1
SOU EXTENSION 1 FILED
17/11/2023
EEXT
SOU TEAS EXTENSION RECEIVED
17/11/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
30/05/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/04/2023
PUBO
PUBLISHED FOR OPPOSITION
04/04/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
15/03/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
25/02/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/01/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/01/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/01/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
22/07/2022
GNRT
NON-FINAL ACTION E-MAILED
22/07/2022
CNRT
NON-FINAL ACTION WRITTEN
22/07/2022
DOCK
ASSIGNED TO EXAMINER
20/07/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
13/07/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/07/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/07/2022
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
04/11/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/11/2021
NWAP
NEW APPLICATION ENTERED
18/10/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace A2 BIO ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.